Please login to the form below

Not currently logged in
Email:
Password:

selumetinib

This page shows the latest selumetinib news and features for those working in and with pharma, biotech and healthcare.

Shock for AZ as MYSTIC trial stumbles at first hurdle

Shock for AZ as MYSTIC trial stumbles at first hurdle

as well as Imfinzi which is already approved for bladder cancer and other drugs such as AZ's MEK inhibitor selumetinib.

Latest news

  • Strong Tagrisso soothes AZ as US sales plummet Strong Tagrisso soothes AZ as US sales plummet

    Meanwhile in its targeted oncology portfolio AZ is also expecting to file BTK inhibitor acalabrutinib for B-cell malignancies later this year, with MEK inhibitor selumetinib for thyroid cancer and  moxetumomab

  • AZ's selumetinib stumbles at last fence in lung cancer AZ's selumetinib stumbles at last fence in lung cancer

    Moreover, it is not the first time that selumetinib has failed to pass muster in a late-stage trial. ... in NSCLC - would move first-line with targeted therapies such as selumetinib used later.

  • AZ gets orphan status for selumetinib in thyroid cancer AZ gets orphan status for selumetinib in thyroid cancer

    AZ gets orphan status for selumetinib in thyroid cancer. Drug already in phase III testing for KRAS-mutant advanced NSCLC. ... AstraZeneca has claimed orphan drug status in the US for selumetinib - one of its second-tier oncology prospects - as a

  • Setback for AZ's MEK inhibitor selumetinib Setback for AZ's MEK inhibitor selumetinib

    Setback for AZ's MEK inhibitor selumetinib. Drug fails at phase III in uveal melanoma. ... The phase III SUMIT trial of selumetinib in combination with dacarbazine for metastatic uveal melanoma did not meet its primary endpoint of progression free

  • AstraZeneca earmarks $285m for Swedish biologics expansion AstraZeneca earmarks $285m for Swedish biologics expansion

    The Anglo-Swedish company's biologics pipeline also includes a number of orphan drugs, including uveal melanoma treatment selumetinib and tremelimumab for malignant mesothelioma.

More from news
Approximately 3 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    But now hopes are high for two late-stage drugs: olaparib and selumetinib. ... With selumetinib you've now got that plus another 20-25 per cent of NSCLC cases - people with the KRAS mutation.”.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics